https://www.mynewsdesk.com/se/exact-sciences-sweden Mynewsdesk RSS - pressmeddelanden, nyheter och blogginlägg. https://www.mynewsdesk.com/se/exact-sciences-sweden https://www.mynewsdesk.com/assets/graphics/logos/logo-small-9892f98564f91864075bd14001f8470f2f9bf254729c37044b4b1ac9b0db6b40.png 128 23 sv 15 Wed, 11 Mar 2026 10:08:31 +0100 I vårt grannland Finland finjusteras behandling av bröstcancer bland annat med hjälp av genomtestet Oncotype DX®, som visar vilka patienter som sannolikt kommer att ha nytta av postoperativ cytostatika. https://www.mynewsdesk.com/se/exact-sciences-sweden/pressreleases/ett-genomtest-hjaelper-till-att-bedoema-behov-av-cytostatika-3436874?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/exact-sciences-sweden/pressreleases/ett-genomtest-hjaelper-till-att-bedoema-behov-av-cytostatika-3436874?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Exact Sciences Sweden AB Fri, 27 Feb 2026 09:47:37 +0100 https://www.mynewsdesk.com/se/exact-sciences-sweden/pressreleases/fler-aen-2-miljoner-patienter-i-vaerlden-har-nyttjat-oncotype-dx-breast-recurrence-score-r-foer-mer-informerade-behandlingsbeslut-3434795?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/exact-sciences-sweden/pressreleases/fler-aen-2-miljoner-patienter-i-vaerlden-har-nyttjat-oncotype-dx-breast-recurrence-score-r-foer-mer-informerade-behandlingsbeslut-3434795?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Exact Sciences Sweden AB Mon, 03 Nov 2025 11:25:36 +0100 https://www.mynewsdesk.com/se/exact-sciences-sweden/news/behoever-alla-broestcancerpatienter-cytostatikabehandling-502844?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/exact-sciences-sweden/news/behoever-alla-broestcancerpatienter-cytostatikabehandling-502844?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Exact Sciences Sweden AB Mon, 01 Sep 2025 13:31:13 +0200 https://www.mynewsdesk.com/se/exact-sciences-sweden/news/innovativt-test-kan-underlaetta-beslut-om-cytostatikabehandling-vid-broestcancer-500528?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/exact-sciences-sweden/news/innovativt-test-kan-underlaetta-beslut-om-cytostatikabehandling-vid-broestcancer-500528?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Exact Sciences Sweden AB Tue, 01 Jul 2025 09:36:20 +0200 Exact Sciences, en ledande leverantör av cancerscreening och diagnostiska tester, meddelade idag att man presenterat nya data som ytterligare stärker nyttan av Oncotype DX Breast Recurrence Score®-tester på den 19:e St. Gallen International Breast Cancer Conference i Wien, Österrike https://www.mynewsdesk.com/se/exact-sciences-sweden/pressreleases/nya-data-visar-att-exact-sciences-oncotype-dx-r-tester-har-en-positiv-inverkan-paa-patientvaarden-och-vaardens-effektivitet-3393013?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/exact-sciences-sweden/pressreleases/nya-data-visar-att-exact-sciences-oncotype-dx-r-tester-har-en-positiv-inverkan-paa-patientvaarden-och-vaardens-effektivitet-3393013?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Exact Sciences Sweden AB